Anavex Life Sciences Corp (AVXL)
9.11
+0.09
(+1.00%)
USD |
NASDAQ |
Nov 22, 16:00
9.075
-0.04
(-0.38%)
After-Hours: 20:00
Anavex Life Sciences Cash from Financing (Quarterly): 4.55M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.55M |
| March 31, 2024 | 7.277M |
| December 31, 2023 | 0.059M |
| September 30, 2023 | 2.056M |
| June 30, 2023 | 9.003M |
| March 31, 2023 | 18.33M |
| December 31, 2022 | 0.258M |
| September 30, 2022 | 0.0025M |
| June 30, 2022 | 6.910M |
| March 31, 2022 | 11.84M |
| December 31, 2021 | 2.540M |
| September 30, 2021 | 2.223M |
| June 30, 2021 | 89.22M |
| March 31, 2021 | 35.82M |
| December 31, 2020 | 25.98M |
| September 30, 2020 | 7.885M |
| June 30, 2020 | 5.100M |
| March 31, 2020 | 4.368M |
| December 31, 2019 | 11.00M |
| September 30, 2019 | 3.471M |
| June 30, 2019 | 9.292M |
| March 31, 2019 | 3.074M |
| December 31, 2018 | 1.945M |
| September 30, 2018 | 1.156M |
| June 30, 2018 | 2.259M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.4289M |
| December 31, 2017 | 4.228M |
| September 30, 2017 | 4.839M |
| June 30, 2017 | 4.416M |
| March 31, 2017 | 2.888M |
| December 31, 2016 | 15.13M |
| September 30, 2016 | 1.323M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | -0.00 |
| December 31, 2015 | 1.810M |
| September 30, 2015 | 8.763M |
| June 30, 2015 | 3.081M |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.4119M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | -0.0539M |
| March 31, 2014 | 9.445M |
| December 31, 2013 | 0.1882M |
| September 30, 2013 | 0.8279M |
| June 30, 2013 | 0.0333M |
| March 31, 2013 | 0.05M |
| December 31, 2012 | 0.20M |
| September 30, 2012 | 0.2451M |
| June 30, 2012 | 0.0783M |
| March 31, 2012 | 0.2838M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.0025M
Minimum
Sep 2022
89.22M
Maximum
Jun 2021
12.86M
Average
6.910M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| Microbot Medical Inc | 0.633M |
| Alaunos Therapeutics Inc | 0.00 |
| SELLAS Life Sciences Group Inc | 19.69M |
| Galectin Therapeutics Inc | 10.00M |
| Oragenics Inc | 3.766M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.18M |
| Free Cash Flow | -30.00M |
| Free Cash Flow Per Share (Quarterly) | -0.0613 |
| Free Cash Flow Yield | -3.98% |